Alzinova reports positive results from pharmacology study

2016-09-05 15:00

Alzinova has completed a second pharmacological study of the vaccine ALZ-101 in an animal model. The study addressed the immune system’s ability to respond to the vaccine formulated in different amounts of adjuvant, and also evaluated if there were any toxic effects after two and three doses. A clear dose-response was observed, and after three treatments a very strong immune response was obtained that was not associated with any findings suggestive of systemic toxicity.